sciencera

The world doesn't suffer from a shortage of biological ideas. It suffers from translation. Every year, researchers identify peptides that could reshape pharma, agriculture, vet, aquaculture, industrial materials, and cosmetics. Most never reach the world. A thread on what that means, and what we're building. 🧵

Vertical spotlight: Human health. GLP-1 analogs. Antimicrobial peptides. Oncology candidates. Wound healing. Vaccine adjuvants. The peptide drug market is real, over 100 FDA-approved peptide therapeutics exist today. What's broken is the path for the next 100. Fragmented funding. Unverifiable lab work. IP locked in expensive law firms. Clinical evidence disconnected from prior assay data. Sciencera's translation infrastructure handles all six verticals natively human health included. Regulatory frameworks in model: FDA, EMA, BPOM, ICH-GCP, 21 CFR Part 11, HIPAA, GMP, GLP.

If you've been building in DeSci and wondering why peptides specifically Same translation problem as any biotech asset. But peptides are uniquely positioned: synthesizable in weeks, active across six distinct markets, and facing regulatory frameworks that are already mapped. The bottleneck has always been the path. Not the molecule. Researchers, reviewers, labs: app.sciencera.tech is open.

GLP Good Laboratory Practice. Not a suggestion. A regulatory framework that governs how lab studies are planned, performed, monitored, and reported. If a lab doesn't operate under GLP, its data may not hold up with FDA, EMA, or BPOM. Sciencera Lab Marketplace: GLP compliance is a verified attribute on every lab profile, not a self-reported checkbox.

What's live on app.sciencera.tech today: · Research Portal hypothesis submission and peer review flow · AI Lab GPT-4o assisted research drafting · Labs Directory browse and filter verified lab profiles · Academy four curriculum tracks, task bank active · @solana wallet integration @phantom , @solflare , @Ledger Three months of work. Now open. app.sciencera.tech

Unpopular take: Most "DeSci" protocols launched a token before they had science. We built a research portal, two on-chain programs, and an academy curriculum first. The token comes when it adds value, not when it raises money. Trust before liquidity. Always. @solana @sciencera_ofc

Translation, not speculation. The product is the network. sciencera.tech docs.sciencera.tech

Tokens follow trust, not the other way around. Reputation first (soulbound). Milestone receipts second. Project and IP tokens only after scientific gates pass. Broader network token only after real usage. This protects the network from the failure mode that defined crypto-biotech so far: liquidity before legitimacy.

The world doesn't suffer from a shortage of biological ideas. It suffers from translation. Every year, researchers identify peptides that could reshape pharma, agriculture, vet, aquaculture, industrial materials, and cosmetics. Most never reach the world. A thread on what that means, and what we're building. 🧵

Every peptide enters six possible markets: Human health · Veterinary · Agriculture · Aquaculture · Industrial · Cosmetics Same molecule class. Six regulatory worlds. One translation problem. That's why we don't pick a vertical. We pick the path. sciencera.tech